🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ICYMI: Our Chairman & co-CEO Helmy Eltoukhy joined Bloomberg’s @CarolMassar & Romaine Bostick at #MIGlobal to share how Guardant is using blood-based testing, DNA sequencing & AI to detect cancer earlier, speed up diagnosis & lower healthcare costs. youtube.com/watch?v=vrZFzM…

Introducing the Guardant Hereditary Cancer test — our germline test designed to identify inherited genetic variants associated with cancer risk across more than 12 tumor types, helping cancer care teams provide optimal patient care.

Today we announced the addition of an extensive suite of immunohistochemistry (IHC) testing to our portfolio of tumor molecular profiling tests, further supporting oncologists in identifying tumor subtypes and matching cancer patients to the most effective targeted therapies.

Improving lung cancer care through genomics! The LAA applauds Guardant Health & 🧬EU Coalition for Comprehensive Genomic Profiling 's recommendations to boost access to Comprehensive Genomic Profiling (CGP) for more patients. 🔗: ecgp.eu/2025/03/04/the…

We’re looking forward next week's 2025 ASCO Annual Meeting, where we’ll share data from 19+ studies showcasing the critical role of our liquid biopsy tests in cancer screening, therapy selection, & recurrence monitoring. Stop by booth #25077 at #ASCO25 to learn more. Details:

We’re excited to introduce nearly a dozen new applications for our Guardant360® Liquid test, further enhancing its ability to identify biomarkers and subtype cancers from a blood sample. Powered by our Guardant Infinity™ platform, these new capabilities enable clinicians to

Join us at #ASCO25 for an exclusive event showcasing how our Guardant Infinity™ platform is propelling patient-centered care into the future. Discover how we’re unlocking new possibilities across the patient journey and redefining precision oncology through innovation and

NHS England's achievement in becoming the first healthcare system in the world to bring liquid biopsy into routine cancer care is a significant milestone and we are honored to have worked on the NHS pilot study, in collaboration with The Royal Marsden NHS Foundation Trust and NHS England, which

At #ASCO25 yesterday, we shared results from the largest study to date evaluating ctDNA in #ColonCancer, highlighting the power of our Guardant Reveal™ test to inform critical treatment decisions.

The future of precision oncology is here. Join us at #ASCO25, booth #25077, to discover the pivotal role of liquid biopsy in transforming cancer care and improving patient outcomes.

Today we announced results from the Phase III SERENA-6 trial, demonstrating the clinical value of our Guardant360® CDx test in detecting and treating emerging resistance in advanced #BreastCancer ahead of radiological progression. Study findings were presented at #ASCO25 and

Results from the SERENA-6 Phase III trial, presented at #ASCO25 and published in NEJM, show how Guardant360® CDx can catch emerging ESR1 mutations in advanced breast cancer—giving clinicians a chance to adjust treatment before cancer progresses.

We’re proud to share that the National Comprehensive Cancer Network (NCCN) has included our Shield™ blood test in its updated #ColorectalCancer screening guidelines. Marking a pivotal step forward in expanding #PatientAccess to an innovative, blood-based screening option.

Featured in The New York Times: Our Guardant360® CDx test is helping revolutionize #BreastCancer treatment by detecting drug resistance before it shows up on scans—enabling timely treatment changes and improving patient outcomes. nytimes.com/2025/06/01/hea…

We're honored to announce that our Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. FDA.